Login to your account

Username *
Password *
Remember Me
Phase 2 RCT | Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease.

Phase 2 RCT | Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease.

Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease: a randomised, double-blind, placebo-controlled, phase 2 study – The Lancet Respiratory Medicine   Commentary on Twitter NEW Research—Pirfenidone slowed the rate of decline of FVC over time in patients with RA-ILD* Being presented at #ERSCongress, ALERT 3 session, Sept 5 from […]

The post Phase 2 RCT | Safety, tolerability, and efficacy of pirfenidone in patients with rheumatoid arthritis-associated interstitial lung disease. appeared first on Links Medicus.

Lu 366 fois
Évaluer cet élément
(0 Votes)

About Author

Laissez un commentaire

Assurez-vous d'entrer toutes les informations requises, indiquées par un astérisque (*). Le code HTML n'est pas autorisé.